Chemical and pharmacokinetic characteristics of P2Y12 receptor inhibitorsa
| Compound | Clopidogrel | Prasugrel | Ticagrelor | Cangrelor |
|---|---|---|---|---|
| Marketed name | Plavix | Effient (US) | Brilinta (US) | Kengreal (US) |
| Efient (EU) | Brilique or Possia (EU) | Kengrexal (EU) | ||
| Reversibility | Irreversible | Irreversible | Reversible | Reversible |
| Administration route | Oral | Oral | Oral | Intravenous |
| Frequency of administration | Once daily | Once daily | Twice daily | Bolus plus infusion |
| Onset of effect | 2–8 hours | 30 min to 4 hours | 30 min to 4 hours | Immediate |
| Duration of effect | 5–7 days | 7–10 days | 3–5 days | 30–60 min |
| Halflife | 6 hours | 7 hours | 8 hours | 3–5 min |
| Apparent volume of distribution | 6–72 L | 44–68 L | 88 L | 3.9 L |
| Plasma protein binding | 98% | 98% | 99.7% | 97%–98% |
| Prodrug | Yes | Yes | No | No |
| Influenced by genetic variation | Yes | No | No | No |
↵a Modified from Aguilar-Salinas et al,11 2019, with permission from BMJ Publishing Group Ltd.